<DOC>
	<DOCNO>NCT00275275</DOCNO>
	<brief_summary>A conversion study Mirapex ( pramipexole ) Requip ( ropinirole ) control release ( CR ) patient Parkinson 's disease determine appropriate conversion ratio side effect relate drug .</brief_summary>
	<brief_title>Pramipexole Conversion Ropinirole Controlled Release ( CR )</brief_title>
	<detailed_description>Three different arm use study . Each three cohort treat sequentially . Each participant take Mirapex PD convert Requip CR 1 3 conversion factor ( mg : mg ) : 1:3 , 1:4 1:5 Mirapex day Requip CR . The first five subject cohort initial dose administer clinic monitor orthostatic change . Assessments motor function conversion do .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Ropinirole</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Diagnosis Parkinson Disease Currently take pramipexole Never take Requip CR Can significant adverse effect standard Requip Can atypical PD due drug , metabolic disorder , encephalitis degenerative disease Can unstable medical condition Can take concurrent monoamine oxidase inhibitor except selegiline ( 10mg per day le ) Female patient childbearing potential must use effective method contraception . Can pregnant lactating . This may complete list ; may additional criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>PD</keyword>
	<keyword>Parkinson 's</keyword>
</DOC>